Proactive Investors - Run By Investors For Investors

Imugene initiates pan-Asia trial of gastric cancer treatment therapy

Imugene initiates pan-Asia trial of gastric cancer treatment therapy

Imugene Ltd (ASX:IMU), a clinical stage immuno-oncology company, has initiated a pan-Asia trial of the company’s HER-Vaxx therapy for gastric cancer patients by making a regulatory package submission for the Phase 1b/2 study in Hong Kong.

This filing represents the first submission to various regulators across Asia to initiate clinical testing of Imugene’s HER-Vaxx therapy, given the high unmet need in this area for patients who have HER-2 positive gastric cancer.

HER-Vaxx is a cancer immunotherapy designed to treat HER-2 positive gastric cancer, a cancer with increased levels of a growth-promoting protein called the HER-2 receptor.

Immuno-oncology is a relatively new but highly promising field that uses the method of activating a patient's immune system against tumour growth.

In conjunction with Novotech, Imugene’s contract research organisation for the study, the company has filed to initiate the study with the Department of Health of Hong Kong.

The proposed HER-Vaxx Phase 1b/2 study will be conducted in two parts.

The initial Phase 1b will enrol up to 18 patients to be treated with HER-Vaxx in combination with chemotherapy to interrogate three dose levels.

This first stage is to obtain safety, immunogenicity (a measure of how many of the HER-2 antibodies are produced), evaluate the booster schedule and determine the optimal dose to take into the Phase 2 study.

The larger, open label Phase 2 study will enrol around 68 patients randomised into two arms of either HER-Vaxx plus standard-of-care or standard-of-care alone.

Imugene has identified eight study sites in Asia to participate in the Phase 1b part of the study. Regulatory filings in other jurisdictions will be done in the next two months.

The principal investigator for Imugene’s Hong Kong site will be Dr Thomas Yau, one of Hong Kong’s leading medical oncologists, whose main research priority is gastrointestinal oncology.


Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

February 20 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
May 09 2019
Here we take a look under the hood of Shield Therapeutics
January 15 2019
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use